1. Home
  2. RGCO vs ADAG Comparison

RGCO vs ADAG Comparison

Compare RGCO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RGC Resources Inc.

RGCO

RGC Resources Inc.

HOLD

Current Price

$23.62

Market Cap

233.9M

Sector

Utilities

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$4.19

Market Cap

260.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGCO
ADAG
Founded
1912
2011
Country
United States
China
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.9M
260.3M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
RGCO
ADAG
Price
$23.62
$4.19
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$22.70
$8.25
AVG Volume (30 Days)
7.3K
218.8K
Earning Date
05-07-2026
04-01-2026
Dividend Yield
3.93%
N/A
EPS Growth
11.21
N/A
EPS
1.31
N/A
Revenue
$95,334,212.00
N/A
Revenue This Year
$11.06
N/A
Revenue Next Year
$2.89
N/A
P/E Ratio
$18.81
N/A
Revenue Growth
12.63
N/A
52 Week Low
$19.68
$1.44
52 Week High
$26.63
$4.75

Technical Indicators

Market Signals
Indicator
RGCO
ADAG
Relative Strength Index (RSI) 55.96 62.22
Support Level $20.80 $3.21
Resistance Level N/A $4.66
Average True Range (ATR) 0.81 0.37
MACD 0.09 0.08
Stochastic Oscillator 47.52 80.57

Price Performance

Historical Comparison
RGCO
ADAG

About RGCO RGC Resources Inc.

RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: